Analyst Conference Summary


conference date: February 14, 2018 @ 5:00 AM Pacific Time
for quarter ending: December 31, 2017 (Q4, fourth quarter 2017)

Forward-looking statements

Overview: .

Comparisons to year-earlier periods are pro-forma.

Basic data (GAAP):

Revenue was $ million, up % sequentially from $296.1 million, and up % from $ million year-earlier.

Net income was $ million, down % sequentially from $67.9 million, and down % from $ year-earlier.

EPS (diluted) was $, down % sequentially from $0.63, and down % from $ year-earlier.



Conference Highlights:

John Cox, CEO of Bioverativ, said "

Non-GAAP results: net income $ million, down % sequentially from $87.1 million. EPS $, down % sequentially from $0.80.

Eloctate revenue was $ million, up % sequentially from $186.3 million, and up % y/y from $ million.

Alprolix revenue was $ million, down % sequentially from $88.5 million and up % from $ million year-earlier.


Cash and equivalents ended at $ million, up sequentially from $224.1 million. Cash flow from operations was $ million. No debt.

Started a BIVV001 Phase 1/2a study for once weekly or less frequent dosing of FVIII in the second half of 2017.

The BIVV009 phase 3 trials for cold agglutinin disease

ST-400 for beta-thalassemia Phase 1 enrollment should start in the first half of 2018.

Cost of sales was $ million. R&D expense $ million. SG&A expense $ million. Total expenses $ million. Leaving income from operations of $ million. Other income $ million. Income tax expense $ million.

Cost of sales include royalties to Sobi. [But revenue includes Sobi collaboration sales in Europe].

Continues to review tax planning strategies due to the high tax rate.

Vision is to become the leading rare blood disorders company.



BIVV OpenIcon main page (access to past analyst conference notes)

OpenIcon Analyst Conference Summaries Main Page



More Analyst Conference Pages:



Disclaimer: My analyst call summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.

Copyright 2017 William P. Meyers